2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults

By afschroeder • April 2, 2026

Shumaker AH, Bhimraj A, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Shafer RW, Tien PC, Baden LR, Cawcutt K, Chiotos K, Dzierba AL, Hardy EJ, Johnson S, Kim AY, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Oliveira CR, Pearson JC, Riley L, Shoham S, Tebas P, Willis Z, Wolf J, Loveless J, Morgan RL, Falck-Ytter Y, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults. Clin Infect Dis. 2026 Apr 1:ciaf680. doi: 10.1093/cid/ciaf680. Epub ahead of print. PMID: 41920902.

Tags: covid-19, guideline, Harbor UCLA, Infectious Diseases, molnupiravir, nirmatrelvir/ritonavir, Publications, remdesivir

Advancements in Artificial Intelligence for Enhanced Diagnosis and Prognosis in Cardiac CT: a Comprehensive Review and Future Perspectives

Adabifirouzjaei F, Budoff M, Nomeli M. Advancements in Artificial Intelligence for Enhanced Diagnosis and Prognosis in Cardiac CT: a Comprehensive Review and Future Perspectives. Curr[...]

On methodological approaches for non-invasive characterization of muscle oxygen uptake recovery kinetics

Marciano A, Rossiter HB. On methodological approaches for non-invasive characterization of muscle oxygen uptake recovery kinetics. Exp Physiol. 2026 Nov 6. doi: 10.1113/EP094185. Epub ahead[...]

Exanthematous drug eruption with reactive T-cell atypia in a patient with accelerated chronic lymphocytic leukemia

Dong S, Jaeger ZJ, Hinds B, Weiss DI, Schneider J, Liou YL. Exanthematous drug eruption with reactive T-cell atypia in a patient with accelerated chronic[...]